Tadalafil

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Tadalafil

Examples of brand names: Cialis [EU/DE]; Adcirca [EU/DE]

ATC code: G04BE08

Main use (for orientation): Erectile dysfunction; pulmonary hypertension

Documented research summary

Tadalafil inhibited CBD-induced TRPV2 calcium influx in rat urothelial cells (29566267). A cell-physiology finding, not clinical tadalafil–CBD pharmacokinetics or a dosing recommendation.

Uncertainties and limitations

Documented individual title/abstract review with selected relevant full texts; not an exhaustive worldwide systematic review and no independent human professional approval. Missing data do not establish safety. All 28 cannabinoids define the search scope, not 28 clinically studied pairs per active substance.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0467

Type of result: Context-specific finding

Observation: Tadalafil inhibited CBD-induced calcium responses; additional ATP endpoints were investigated in tissue.

Mechanism: Tadalafil affects CBD-induced TRPV2-dependent signals in the urothelium.

Study type: Animal cell/tissue experiments, pharmacodynamics

Context studied: Rat urothelium; including tadalafil 10 µM in the calcium experiment and a higher-concentration context in the ATP test.

Clinical interpretation: Applicability to humans is unresolved; preclinical endpoint, not clinical evidence of treatment efficacy or safety.

Limitations and uncertainties: Experimental concentrations, not a clinical bladder-treatment or PDE5/CBD drug–drug interaction.

Original sources for this finding: Tadalafil attenuates hypotonicity-induced Ca2+ influx via TRPV2 and TRPV4 in primary rat bladder urothelial cell cultures. [VF_P_29566267]

References and access status

[VF_L_D0361] ALYQ (TADALAFIL) TABLET, FILM COATED [TEVA PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2026

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_29566267] Tadalafil attenuates hypotonicity-induced Ca2+ influx via TRPV2 and TRPV4 in primary rat bladder urothelial cell cultures.

Original source / bibliographic reference

Authors: Dong X, Nakagomi H, Miyamoto T, Ihara T, Kira S, Sawada N, Mitsui T, Takeda M.

Year: 2018

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1002/nau.23423

PMID: 29566267

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility